Payment overview · 2025
General Payments
$2,751.98
130 reported records · 23 companies
Healthcare provider profile · identity verified
Nicholas Simpson
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · ST. LOUIS, MO · NPI 1174174775
Verified facts
What the public records show
CMS Open Payments records show Nicholas Simpson received $2,751.98 in general payments during 2025 across 130 reported records.
UCB, Inc. accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kevzara.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEVZARA as an associated drug or biological on 5840 records involving 2002 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kevzara by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $635.17 | 23.1% | 25 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $398.23 | 14.5% | 15 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $256.90 | 9.3% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $237.77 | 8.6% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $208.45 | 7.6% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $177.78 | 6.5% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $173.77 | 6.3% | 13 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $156.21 | 5.7% | 7 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $151.44 | 5.5% | 4 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $55.85 | 2.0% | 2 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.07 | 1.5% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $29.19 | 1.1% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $27.39 | 1.0% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $24.45 | 0.9% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $23.74 | 0.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.02 | 0.8% | 1 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $22.93 | 0.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $21.65 | 0.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.96 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.01 | 0.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.07 | 0.7% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $14.67 | 0.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.26 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,674.99 | 129 |
| Education | $76.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $616.55 | 23 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $338.22 | 12 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $256.90 | 10 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $196.57 | 10 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $173.77 | 13 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $160.97 | 17 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $151.44 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $129.15 | 5 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $77.71 | 3 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $55.85 | 2 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $55.85 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.20 | 2 | 2025 |
Source payment records
|
|||||
| Empaveli Normalized: empaveli |
Drug | Apellis Pharmaceuticals, Inc. | $41.07 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $39.94 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $29.19 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $27.39 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| MONOVISC Normalized: monovisc |
Device | DePuy Synthes Sales Inc. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $18.62 | 2 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| ILARIS Normalized: ilaris |
Drug | Novartis Pharmaceuticals Corporation | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $10.20 | 1 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $9.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| KEVZARA kevzara |
2025 | Kevzara | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | KEVZARA open payments reported associated product |
CMS Open Payments — General Payments 5840 supporting records · 2002 recipient NPIs · example record 1233195032 |
Kevzara · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 601 | 285 |
| Methotrexate | Methotrexate Sodium | 456 | 226 |
| Diclofenac Sodium | Diclofenac Sodium | 331 | 128 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 286 | 118 |
| Gabapentin | Gabapentin | 248 | 98 |
| Sulfasalazine Dr | Sulfasalazine | 237 | 89 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 225 | 97 |
| Leflunomide | Leflunomide | 160 | 83 |
| Azathioprine | Azathioprine | 140 | 75 |
| Meloxicam | Meloxicam | 114 | 43 |
| Methylprednisolone | Methylprednisolone | 106 | 79 |
| Celecoxib | Celecoxib | 93 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 40 |
| Folic Acid | Folic Acid | 68 | 38 |
| Enbrel Sureclick | Etanercept | 56 | 18 |
| Omeprazole | Omeprazole | 55 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 23 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 43 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 18 |
| Baclofen | Baclofen | 28 | 14 |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 26 | 12 |
| Trazodone Hcl | Trazodone Hcl | 26 | 13 |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Humira(Cf) Pen | Adalimumab | 22 | suppressed |
| Orencia Clickject | Abatacept | 19 | suppressed |
| Allopurinol | Allopurinol | 16 | 11 |
| Lidocaine | Lidocaine | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Actemra Actpen | Tocilizumab | 13 | suppressed |
| Kevzara | Sarilumab | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,751.98 · 130 records | UCB, Inc. | APRETUDE, Actemra, BENLYSTA, Bimzelx, Briviact, CABENUVA, COSENTYX, CRYSVITA, DOVATO, EGRIFTA, EMBLAVEO, ENBREL, EVENITY, Empaveli, FARXIGA, IBSRELA, ILARIS, KEVZARA, KRYSTEXXA, Kerendia, MAVYRET, MONOVISC, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORENCIA, OTEZLA, PEMGARDA, RINVOQ, RUKOBIA, SAPHNELO, SKYRIZI, TAVNEOS, TREMFYA, TROGARZO, VOWST, Wegovy, XELJANZ | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kevzara play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GENZYME CORPORATION?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error